Russian Bioregulator Peptides: Thymalin and Others

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

Thymalin, Cardiogen, Cortagen and Crystagen belong to a distinct research tradition: the peptide bioregulator programme associated with Vladimir Khavinson and the St Petersburg Institute of Bioregulation and Gerontology. Reading this literature well means understanding both the underlying idea and the specific reasons it is harder to evaluate than most.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

The class at a glance

Name	Type	Associated tissue	Defined composition?
Thymalin	Tissue-derived preparation	Thymus / immune	No — a mixture
Cardiogen	Short synthetic peptide	Cardiac	Yes
Cortagen	Short synthetic peptide	Cerebral cortex	Yes
Crystagen	Short synthetic peptide	Immune	Yes
Epithalon	Synthetic tetrapeptide	Pineal	Yes

Note the split in the first column. Some members are tissue extracts, others are defined synthetic peptides. These are not the same kind of object, and treating a mixture and a tetrapeptide as members of one coherent class is the first interpretive trap.

The central idea

The programme’s hypothesis is that very short peptides — often two to four residues — act as regulators of gene expression, and that such peptides derived from a given tissue preferentially influence that tissue. The proposed mechanism involves direct interaction with DNA or chromatin rather than classical receptor signalling.

The idea is not inherently implausible. Short peptides can enter cells, and peptide-nucleic acid interactions are chemically real. The 2023 study by Linkova and colleagues illustrates how it is tested: it examined the dipeptides KE (lysine-glutamate) and EW (glutamate-tryptophan) present in Thymalin, looking at gene expression and protein synthesis endpoints. A dipeptide influencing transcription would be a striking result, which is exactly why it needs strong evidence.

Why Thymalin is harder to work with than it looks

Thymalin is described as a peptide preparation from thymus tissue. That means a mixture whose composition depends on source material and process, and which can vary between batches and manufacturers.

Three consequences for experimental work follow:

Reproducibility across sources is not assured. Two vials labelled Thymalin need not contain the same thing.
Mechanism cannot be attributed to a molecule without first identifying which component is responsible, which is what the KE / EW study sets out to do.
Characterisation is harder. A mixture has no single mass or purity figure, so a certificate of analysis means something different than it does for a synthetic peptide.

This is the same problem thymosin fraction 5 posed to immunology decades earlier, and it was resolved there by isolating the individual peptides. See thymosin alpha-1 for how that worked out.

Reading the literature fairly

Three features of this body of work need to be named plainly, without dismissing it:

Feature	Why it matters
Concentrated authorship	A large share of the work comes from one network. Independent replication carries more weight than additional papers from the same programme.
Russian-language publication	Many early papers are in journals with limited indexing, often available only as abstracts in English. The 2002 geroprotective paper is one such case.
Study size and design	Reported studies are often small, and design details can be hard to assess from the available text.

Against that, there is more recent work in indexed international journals, which is the better place to start. The 2020 Thymalin paper on human hematopoietic stem cell differentiation and the 2022 study in the THP-1 monocyte/macrophage line are both in that category, and the latter is useful because a defined cell line with standard inflammatory readouts is a system other laboratories can reproduce.

What would strengthen the case

Stating this explicitly is more useful than a verdict. The evidence that would move this field forward is:

Full compositional characterisation of the tissue-derived preparations, so that mixtures become defined.
Direct demonstration of the proposed peptide-DNA or peptide-chromatin interaction with structural methods.
Replication of the tissue-selectivity claim in independent laboratories using matched controls, including scrambled dipeptides.
Dose-response relationships in defined cell systems, rather than single-concentration observations.

Handling in the lab

Store lyophilized material sealed at −20 °C, protected from light and moisture.
For the short synthetic members, reconstitution is straightforward; for tissue-derived preparations follow the supplier’s data sheet, since solubility depends on composition.
Very short peptides are rapidly degraded in biological samples and adsorb readily to surfaces — both effects are larger here than for longer peptides.
Use a scrambled-sequence control for any dipeptide or tripeptide experiment; at this length, composition effects are easily mistaken for sequence effects.
Aliquot stocks and keep working solutions cold. See storing reconstituted peptides.
Concentration maths: peptide reconstitution calculator.

Our Thymalin research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report.

Open questions

What is the full composition of the tissue-derived preparations, batch to batch?
Is there direct structural evidence for the proposed peptide-chromatin interaction?
Does the tissue-selectivity claim hold in independent hands?

What is Epithalon?
What is Thymosin Alpha-1?
What “research use only” means

Frequently asked questions

What are Russian bioregulator peptides?

A group of short peptide preparations developed largely in St Petersburg, associated with Vladimir Khavinson and the St Petersburg Institute of Bioregulation and Gerontology. The programme includes tissue extracts such as Thymalin and short synthetic peptides such as Cortagen and Epithalon.

Is Thymalin a single peptide?

No. Thymalin is described as a peptide preparation derived from thymus tissue, that is, a mixture, rather than one defined molecule. A 2023 study examined the contribution of the dipeptides KE and EW within it, which illustrates the point.

What are Cardiogen, Cortagen and Crystagen?

Short synthetic peptides from the same research programme, each associated by its developers with a particular tissue: cardiac, cortical and immune respectively. The naming convention indicates intended tissue association, not an established mechanism.

Why is this literature harder to assess?

Much of it was published in Russian-language journals, often with limited indexing and small study sizes, and a large share comes from one research network. Independent replication outside that network is comparatively sparse.

Are these peptides the same as Epithalon?

Epithalon comes from the same programme and is its most widely known member. It is a defined tetrapeptide, which makes it easier to study than the tissue-extract preparations.

References

Khavinson VK, et al. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull Exp Biol Med. 2020. PMID: 33237528 https://pubmed.ncbi.nlm.nih.gov/33237528/
Linkova N, et al. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. Int J Mol Sci. 2023. PMID: 37686182 https://pubmed.ncbi.nlm.nih.gov/37686182/
Avolio F, et al. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 2022. PMID: 35408963 https://pubmed.ncbi.nlm.nih.gov/35408963/
Khavinson VKh, et al. [Geroprotective effect of thymalin and epithalamin]. Adv Gerontol. 2002. PMID: 12577695 https://pubmed.ncbi.nlm.nih.gov/12577695/